While anti-CTLA-4 therapy with the monoclonal antibody ipilimumab has improved the overall survival of metastatic melanoma patients (8) compared to anti-PD-1 therapy, a smaller percentage of patients benefited from anti-CTLA-4 treatment, and more immunotherapy-related adverse events were reported (9–11). This evidence concerns the gene CTLA4 and metastatic melanoma.